Compare JBS N.V. Class A Common Shares (JBS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Novo Nordisk A/S — how do they compare? JBS N.V. Class A Common Shares trades at $13.05 (market cap $13.96B), while Novo Nordisk A/S trades at $38.74 (market cap $169.24B). The key difference: Novo Nordisk A/S is far larger — about 12.1× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.31%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Novo Nordisk A/S for 116 Days on average.
| JBS | NVO | |
|---|---|---|
Market Cap | $13.96B | $169.24B |
Volume | 5,326,589 | 9,314,273 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $63.98 |
52-Week Low | $10.86 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $34.93B | $187.94B |
Dividend Yield | 10.31% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Novo Nordisk (NVO) trades at $38.06, down 1.35% on the day, with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and 59.82% ROE, while recent quarterly earnings consistently beat expectations. Technical indicators show oversold conditions with RSI at 85.35, though the stock faces resistance at $39 levels. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews of hemophilia treatments.
NVO presents a compelling value opportunity with a 9.67 P/E ratio below industry averages and 58.98% analyst buy ratings targeting $42.33. Strong cash flow generation ($119.1B operating cash flow) supports dividend payments and strategic acquisitions. Key risks include competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays, but the company's dominant GLP-1 market position and expanding oral formulations provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
